**Supplementary Table 2.** Treatment in evaluated groups of patients.

|  |  |  |  |
| --- | --- | --- | --- |
|   | NMOsd | MS | NPSLE |
| Evaluated patients (n) | 19 | 42 | 35 |
| Steroids  | 8 | 0 | 23 |
| Monotherapy | 5 | 0 | 4 |
| Combined therapy | 3 | 0 | 19 |
| Imunosuppressants  | 5 | 0 | 23 |
|  AZA | 5 | 0 | 5 |
|  CTX | 0 | 0 | 6 |
|  MMF | 0 | 0 | 6 |
|  MTX | 0 | 0 | 7 |
|  Monotherapy | 2 | 0 | 1 |
|  Combined therapy | 3 | 0 | 22 |
| Antimalarials | 0 | 0 | 22 |
|  CQ | 0 | 0 | 12 |
|  HCQ | 0 | 0 | 10 |
| Steroid+immunosuppressant | 3 | 0 | 4 |
| Steroid+antimalarial | 0 | 0 | 1 |
| Immunosuppressant+antimalarial | 0 | 0 | 4 |
| Steroid+immusuppresant+antimalarial | 0 | 0 | 14 |
| Immunomodulation | 1 | 38 | 0 |
|  IFN-b | 0 | 35 | 0 |
|  GA | 1 | 3 | 0 |
| Without treatment | 8 | 0 | 1 |
| No data | 0 | 4 | 3 |

NMOsd: neuromyelitis optica spectrum disorders; MS: multiple sclerosis; NPSLE: neuropsychiatric systemic lupus erythematosus; AZA: azathioprine; CTX: cyclophosphamide; MMF: mycophenolate mofetil; MTX: methotrexate; CQ: chloroquine; HCQ: hydroxychloroquine; IFN-b: interferon beta; GA: glatiramer acetate.